ABSTRACT We have analysed retrospectively 100 consecutive patients with cryptogenic fibrosing alveolitis, who were treated with corticosteroids and followed for at least three years. At 
Fibrosing alveolitis is a clinical syndrome with a notably variable course. Although the first patients described by Hamman and Rich' died within 12 months of the onset of symptoms, a more chronic course is usual. 23 Despite the variability of diagnostic criteria and histological features in the different published studies, there is agreement that factors affecting prognosis include the short-term response to corticosteroid drugs and the cellularity of lung biopsy specimens. 2 We have further evaluated the influence of clinical features, histological findings, and treatment on prognosis in 100 patients with cryptogenic fibrosing alveolitis diagnosed and treated from 1967 to 1979.
Methods
The patients From a total of 113 consecutive patients 13 are excluded from this report as they did not receive corticosteroids. The mean age of the remaining 100 patients at the onset of symptoms was 53 years (range 16-77 years); 51 were women and 49 men.
All patients were followed for at least three years from the time of diagnosis or to death (mean follow-up 6-8 years) . Assessment 19-7 (range 36-92). There was no relationship between these volumes and the prognosis (FVC; p = 044, log rank test).
The mean percentage of the predicted diffusing capacity was 43-2 ± 12-0 (range 11-75). Survival was significantly longer in patients with a TLCO 45 % or more of the predicted value than in patients with lower TLco values (fig 4) . TLco was not measured in three cases with far advanced disease (FVC 32-43% of predicted). There is close agreement on survival in the various reported series. The five-year survival was about 50% in the series of Turner-Warwick et a!3 and Wright et al'4 and slightly higher (60%) in the present series. We excluded, however, 13 patients who were not given steroids and, if these cases are included, the five-year survival was close to 50%. The better survival of young patients and the longer survival associated with lesser radiographic abnormalities have also been noted in other series.314 In addition, we have shown that a more favourable prognosis is related to higher diffusing capacity at presentation.
The correlations between histological appearance, response to steroids, and survival are difficult to compare in different series because of different criteria and methods used in analysis. The presence of more intra-alveolar large mononuclear cells, less fibrosis, and no more than slight alveolar wall thickening has been related to a better steroid response.4514 Other workers have found that patients with a more cellular picture respond to steroid treatment.217 Our histological analysis divided the patients into a mainly inflammatory and a mainly fibrotic group. Patients with a cellular histological picture would correspond to our inflammatory group and these patients showed a better short-term response to steroids and a more favourable long-term outcome. Our findings were, however, not as clearcut as those of Wright et al. 14 The value of needle biopsy in the diagnosis of diffuse lung disease is closely related to the size of the biopsy specimen.'2 Open lung biopsy is the most reliable diagnostic procedure, but in clinical practice the TruCut needle biopsy method can be used successfully. In our material the biopsy was diagnostically helpful in 45 of 54 patients (85%) and open lung biopsy in 12 of 13. The main factor influencing the long-term prognosis was the short-term response to steroid treatment, which is in agreement with the findings of other studies.27 An objective functional improvement was observed in 30 of 100 cases and, in contrast to the results of Turner-Warwick et al,7 the response to steroids was independent of age and sex. The prognostic value of the initial steroid response seems to be better than that of the lung biopsy appearance. In our patients with fibrosing alveolitis a trial of steroid treatment of six months' duration is started irrespective of the nature of the lung biopsy finding. After six months a decision whether or not to continue this treatment is based on the steroid response. Lung biopsy findings do not influence our treatment regimen in most cases. We therefore suggest that lung biopsy is primarily of value in the differential diagnosis of diffuse lung disease rather than for prognostic purposes alone.
